Roginolisib clinical trials
Roginolisib is named as an intervention in 6 current clinical trials in our Italy, UK, Spain, France, Belgium and Australia registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is iOnctura (4). The most-studied condition is Solid Tumor, Adult.
Where Roginolisib is approved
All regulators →- 1 EU orphan designation, most recently for treatment of uveal melanoma (13 Dec 2024, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Roginolisib works
All drug targets →- Uveal melanomaPhase 2
- B-cell chronic lymphocytic leukemiaPhase 1/2
- Mature T-cell and NK-cell non-Hodgkin lymphomaPhase 1/2
- MyelofibrosisPhase 1/2
- Non-small cell lung carcinomaPhase 1/2
- Cutaneous melanomaPhase 1
- MesotheliomaPhase 1
- Primary myelofibrosisPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3683575, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12487, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Roginolisib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Roginolisib
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Roginolisib
12 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| iOnctura | 4 |
| The Lymphoma Academic Research Organisation | 1 |
| St Vincent's Hospital, Sydney | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Italy | 4 | 1 |
| Clinical trials in UK | 3 | 1 |
| Clinical trials in Spain | 3 | 1 |
| Clinical trials in France | 1 | 1 |
| Clinical trials in Belgium | 1 | 0 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Roginolisib trials
How many clinical trials are testing Roginolisib?
6 current trials in our Italy, UK, Spain, France, Belgium and Australia registers name Roginolisib (also registered as IOA-244) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Roginolisib trials recruiting patients?
Yes. 3 of the 6 trials are recruiting: 1 with sites in Italy, 1 with sites in UK, 1 with sites in Spain, 1 with sites in France and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Roginolisib clinical trials?
iOnctura (4), The Lymphoma Academic Research Organisation (1) and St Vincent's Hospital, Sydney (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Roginolisib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Roginolisib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Roginolisib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.